UCB's Global Corporate Website
Welcome to UCB in the United States
  • Healthcare Professionals
  • Patients
  • Investors

    • Categories

    Archives

    Apr

    21

    Earth Day 2023: Our Commitment to Sustainability in the Workplace

    Read More

    Apr

    20

    UCB Showcases Strength and Depth of Neurology Portfolio at 75th American Academy of Neurology (AAN) Annual Meeting

    Read More

    Apr

    17

    UCB Announces FINTEPLA® (fenfluramine) Oral Solution Is Now Descheduled and Is No Longer Listed as a Controlled Substance

    Read More

    Apr

    14

    Recognizing UCB’s Rising Stars: Brittany Blair and Lauren Drowley Recognized by the Healthcare Businesswomen’s Association

    Read More

    Feb

    17

    Patient-First, Patient-Focused: Our Purpose and Promise

    Read More

    Jan

    20

    Employee Spotlight: Ian Crassweller – Leading and Evolving Through Change

    Read More

    Jan

    06

    UCB announces rozanolixizumab BLA for the treatment of generalized myasthenia gravis filed with U.S. FDA and designated for Priority Review

    Read More

    © 2026 UCB, Inc., Smyrna, GA 30080. All rights reserved.
    US-DA-2500920